Search results

Order by most recent / most popular / relevance

Results: 1-10 of 48

U.K. jumps on “pay-to-delay” bandwagon

Fish & Richardson PC
-
United Kingdom, USA
-
April 24 2013

The U.K. Office of Fair Trading ("OFT") jumped on the "pay-to-delay" bandwagon last week when it issued a "Statement of Objections," indicating a

Northern exposure?

Gowling Lafleur Henderson LLP
-
Canada, USA
-
April 4 2013

Davit Akman and John Norman suggest that a recently commenced investigation into alleged "product switching" and statements by the Interim

Courts split on whether to dismiss sham litigation antitrust claims

Hogan Lovells
-
USA
-
July 16 2010

Two federal district courts have recently ruled on the sufficiency of claims brought by parties alleging that brand name drug manufacturers brought "sham" patent infringement litigation against them in violation of antitrust laws, in order to forestall generic entry

Third Circuit rules in favour of FTC view on pharmaceutical patent settlements

Hogan Lovells
-
USA
-
August 9 2012

The US Court of Appeals for the Third Circuit recently issued a decision holding that pharmaceutical patent settlements that restrict generic entry and contain a payment to the generic company are presumptively unlawful under the antitrust laws

Generics demand brand drug samples for ANDA filings

Fish & Richardson PC
-
USA
-
April 11 2013

Tensions between branded pharma companies and their generic competitors are boiling over into court battles over the "right" of generics to demand

Watson and reverse payments: an opportunity to resolve the competing tension between antitrust and patent law under the Hatch-Waxman Act

Proskauer Rose LLP
-
USA
-
March 8 2013

On March 25, the Supreme Court will hear arguments in Federal Trade Commission v. Watson Pharmaceuticals, Inc., and take a step toward concluding

Third Circuit holds that “reverse settlement” payments are prima facie evidence of an antitrust violation, widening Circuit split

Paul, Weiss, Rifkind, Wharton & Garrison LLP
-
USA
-
July 19 2012

The Federal Trade Commission and class action plaintiffs achieved a significant victory this week in their ongoing effort to invalidate “reverse settlement” payments among manufacturers of branded and generic pharmaceuticals

Shionogi Pharma, Inc. v. Mylan, Inc., C.A. No. 10-1077, 2011 WL 2174499 (D. Del. May 26, 2011)

Potter Anderson & Corroon LLP
-
USA
-
June 24 2011

CIMA Labs Inc. (“CIMA”) owns a patent related to the structure of a tablet that masks the taste of a pharmaceutical, and Shionogi Pharma, Inc. (“Shionogi”) is the exclusive licensee of the patent in the United States

Eleventh Circuit deals FTC another setback in Androgel “reverse payment” case

Hogan Lovells
-
USA
-
June 12 2012

On 25 April, the United States Court of Appeals for the Eleventh Circuit unanimously affirmed a district court’s dismissal of the FTC’s antitrust challenge to a so-called "reverse payment" patent settlement involving Solvay Pharmaceutical’s drug Androgel

Eleventh Circuit turns aside FTC challenge to pay-for-delay deal

Shook Hardy & Bacon LLP
-
USA
-
May 3 2012

The Eleventh Circuit Court of Appeals has dismissed an antitrust action filed by the Federal Trade Commission (FTC) against a name-brand prescription drug manufacturer (the patent holder) and generic drug companies that entered into pay-for-delay agreements to settle patent infringement claims filed against the generic drug companies

next >

Search results

U.K. jumps on “pay-to-delay” bandwagon

Northern exposure?

Courts split on whether to dismiss sham litigation antitrust claims

Third Circuit rules in favour of FTC view on pharmaceutical patent settlements

Generics demand brand drug samples for ANDA filings

Watson and reverse payments: an opportunity to resolve the competing tension between antitrust and patent law under the Hatch-Waxman Act

Third Circuit holds that “reverse settlement” payments are prima facie evidence of an antitrust violation, widening Circuit split

Shionogi Pharma, Inc. v. Mylan, Inc., C.A. No. 10-1077, 2011 WL 2174499 (D. Del. May 26, 2011)

Eleventh Circuit deals FTC another setback in Androgel “reverse payment” case

Eleventh Circuit turns aside FTC challenge to pay-for-delay deal

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction